Option Candidate definition

Option Candidate means a Selected Product that meets the Option Candidate Criteria.
Sample 1Sample 2Sample 3
Option Candidate means (a) any Protein Sequences designed, optimized and evolved by or on behalf of either Party or both Parties in the Option Program for the Option Field and (b) those Protein Sequences discovered for the Option Field, prior to the Effective Date, by or on behalf of Codexis, if any.
Sample 1Sample 2Sample 3
Option Candidate has the meaning set forth in Section 2.2.
Sample 1Sample 2

Examples of Option Candidate in a sentence

  • If Artiva in good faith determines that such Option Candidate Data Package is not complete, Artiva shall identify the Information not included in such Option Candidate Data Package that is necessary to make such Option Candidate Data Package complete, and GCLC shall promptly make available such Information to Artiva, which shall then be considered part of the Option Candidate Data Package.

  • If no agreement on such economic terms is reached by the time of the Option Exercise with respect to such Option Candidate, unless the Parties agree otherwise, then the Parties will submit the dispute for resolution pursuant to Section 13.5 and will enter into a Selected Product License Agreement containing terms determined pursuant to such dispute resolution (as may be modified or added to by written agreement of the Parties).

  • When the JSC determines that a Selected Product qualifies as an Option Candidate, the provisions of Section 5 shall apply to such Option Candidate.

  • With respect to each Option Candidate, at such time the JSC determines that a Selected Product qualifies as an Option Candidate, GCLC shall promptly present such Option Candidate to Artiva for its consideration and provide to Artiva all material Information generated by or on behalf of GCLC with respect to such Option Candidate (“Option Candidate Data Package”), which shall include all research and pre-clinical studies performed with respect to such Option Candidate.

  • Changes in deferred income tax assets or liabilities are recognized as a component of tax income or expense in the income statement, except where they relate to items that are recognized in other comprehensive income (actuarial gain or losses) or directly in equity, in which case the related deferred tax is also recognized in other comprehensive income or equity, respectively.

  • GCLC shall make qualified GCLC representatives reasonably available to Artiva (at a JSC meeting or otherwise) for discussion of such Option Candidate Data Package.

  • Artiva may, in its sole discretion, exercise the Option with respect to each Option Candidate (the “Option Exercise”) at any time during the applicable Option Exercise Period upon delivery of written notice of exercise of such Option to GCLC (the “Exercise Notice”).

  • The Option Candidate Data Package shall be subject to review by Artiva to determine whether or not such Option Candidate Data Package is complete with respect to the activities outlined and agreed upon in the R&D Plan and that the Option Candidate meets the Option Candidate Criteria.

  • Following the Delivery Date of the Option Candidate Data Package for an Option Candidate other than AB-101, the Parties shall negotiate in good faith to determine the amount of upfront payments (if applicable), development milestones payments, sales milestone payments and royalty payments to be reflected in the Selected Product License Agreement for such Option Candidate if Option Exercise occurs, where the specific amounts shall reflect [***].

  • Upon such exercise by AstraZeneca, such Option Compound shall become an IND-Ready Option Candidate Drug and subject to AstraZeneca’s obligations pursuant to Section 5.5.1(c).

Related to Option Candidate

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Independent candidate means any candidate who claims not to be affiliated with a political party, and whose name has been certified on the office-type ballot at a general or special election through the filing of a statement of candidacy and nominating petition, as prescribed in section 3513.257 of the Revised Code.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Replacement Candidate means any Candidate Introduced by the Agency to the Client to fill the Engagement following the Introduction of another Candidate whose Engagement either did not commence or was terminated during the first 12 weeks of the Engagement;

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • POC means Point of Compliance. "POE" means Point of Exposure. "PSI" means pounds per square inch.

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Valid write-in candidate means a candidate who has qualified as a write-in

  • Election campaign means any campaign in support of or in

  • Licensed Compound means [***].

  • continuing candidate means any candidate not deemed to be elected, and not excluded,

  • Exempt compound means the same as defined in Rule 2.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Election cycle means the period beginning on the first day persons are eligible to

  • Candidate means the person Introduced by the Agency to the Client for an Engagement including any officer, employee or other representative of the Candidate if the Candidate is a corporate body, and members of the Agency’s own staff;

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • New Product means the Synology-branded hardware product and Synology-branded accessories contained in the original packaging Customer bought from an authorized Synology distributor or reseller. You may see our “New Product” at Product Support Status.

  • Nomination Criteria means the criteria made up of the Over-Riding Nomination Criteria andthe Specific Nomination Factors, and is also referred to as “this Criteria”.

  • Development Milestone Event has the meaning set forth in Section 7.2.1.

  • Examination Criteria means the loan classification criteria employed by, or any applicable regulations of, the Assuming Institution’s Chartering Authority at the time such action is taken, as such criteria may be amended from time to time.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • inherited metabolic disease means a disease caused by an inherited abnormality of body chemistry for which testing is mandated by law;

  • Development Milestone is defined in Section 5.3.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.